Explore
Multiple sclerosis (MS) offers important challenges to understanding its complex genetics and molecular and immunological mechanisms, which eventually lead to relapsing and progressive clinical forms and a constellation of clinical manifestations. Along with the progress in knowledge, disease-modifying treatments and new therapeutic molecules have made an impact on the prognosis of the disease. Essential in the diagnostic identification process of MS is the differentiation of this major demyelinating disease with other inflammatory CNS disorders, including Neuromyelitis Optica and MOG antibody disease. MS is more prevalent in women; therefore, pregnancy and post-partum hormonal and immunological changes typically affect the clinical behavior of the disease. This Special Issue of Biomedicines addresses recent advances in the mechanistic genetic and immunological processes of MS, opening more options to future studies and to the consideration of further therapeutic possibilities. The issue discusses the application of modern therapies, including monoclonal antibodies, some still in the process of complete development, and the current strategies managing progressive MS. The aim of this issue is to stimulate basic and clinical research and promote observations on the ever-expanding and complex field of MS. Advancement in the understanding of the mechanisms and the clinical characterizations of this disease should result in improved therapeutic outcomes that reduce neurological and cognitive disability commonly associated with progressive disease.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 48 times via unglue.it ebook links.
- 48 - pdf (CC BY) at Unglue.it.
Keywords
- anti-CD20
- anti-MOG syndrome
- aquaporin 4-IgG
- association study
- Autoimmunity
- autologous hematopoietic
- Axon
- biomarkers
- CD25
- Clinical Trial
- cognitive dysfunction
- cognitive impairment
- Cortex
- CYBB
- daclizumab
- Demyelinating Diseases
- Demyelination
- disease modifying therapies
- disease modifying therapy
- dress
- drug reaction with eosinophilia systemic symptoms
- generic medicines
- Genetics
- human embryonic
- induced pluripotent
- Innate immune system
- interleukin-2
- medicine
- mesenchymal
- Mitochondria
- monoclonal antibodies
- Multiple Sclerosis
- myelin
- myelin oligodendrocyte glycoprotein
- NADPH Oxidase
- neurodegeneration
- neuromyelitis optica spectrum disorders
- neuronal
- Ocrevus
- oligodendrocyte
- outcome measures
- post-partum
- Pregnancy
- progressive multiple sclerosis
- Reactive Oxygen Species
- relapsing multiple sclerosis
- remyelination
- Rituxan
- Stem Cells
- Treatment
- Tysabri
Links
DOI: 10.3390/books978-3-0365-3097-0Editions